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Background: Tetherin (or BST-2) is an antiviral host restriction factor that suppresses the release of HIV-1 and other
enveloped viruses by tethering them to the cell surface. Recently, it has been demonstrated that tetherin also acts
as an innate sensor of HIV-1 assembly that induces NF-κB-dependent proinflammatory responses. Furthermore, it
has been reported that polymorphisms in the promoter and 3‘ untranslated region of the bst2 gene may affect the
clinical outcome of HIV-1 infection. However, non-synonymous polymorphisms in the bst2 open reading frame
have not yet been described or functionally characterized.
Results: Mining of the Exome Variant Server database identified seven very rare naturally occurring missense
variants of tetherin (Y8H, R19H, N49S, D103N, E117A, D129E and V146L) in human populations. Functional analyses
showed that none of these sequence variants significantly affects the ability of tetherin to inhibit HIV-1 virion
release or its sensitivity to antagonism by HIV-1 Vpu or SIVtan Env, although Y8H alters a potential YxY endocytic
motif proposed to play a role in virion uptake. Thus, these variants do most likely not represent an evolutionary
advantage in directly controlling HIV-1 replication or spread. Interestingly, however, the R19H variant selectively
abrogated the signaling activity of tetherin.
Conclusions: Restriction of HIV-1 virion release and immune sensing are two separable functions of human
tetherin and the latter activity is severely impaired by a single amino acid variant (R19H) in the cytoplasmic part
of tetherin.Background
Tetherin (BST-2, CD317, HM1.24) is an interferon-
induced host restriction factor that inhibits the release of
HIV, Ebola, Lassa, Herpes and other enveloped viruses
from infected cells by tethering nascent virions to the
plasma membrane [1-5]. Tetherin is a dimeric type II
transmembrane protein with a size of 30–36 kDa [6]. It
contains a cytoplasmic N-terminal region, a transmem-
brane domain, a glycosylated coiled-coil extracellular do-
main, and a C-terminal glycosylphosphatidylinositol (GPI)
anchor [6]. The unusual topology of this restriction factor
with both a transmembrane domain and a GPI anchor
allows it to directly tether budding virions to host cells* Correspondence: daniel.sauter@uni-ulm.de; frank.kirchhoff@uni-ulm.de
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reproduction in any medium, provided the orwith one membrane anchor sticking in the virion and the
other one remaining in the cellular membrane [7]. The
coiled-coil domain of tetherin seems to provide confor-
mational flexibility to allow this anchoring process [8].
Most simian immunodeficiency viruses (SIVs), including
the direct precursors of HIV-1 infecting chimpanzees and
gorillas, use their accessory Nef protein to antagonize
tetherin of their respective host species [9-11]. Human
tetherin, however, contains a five amino acid deletion in
its cytoplasmic domain that evolved in hominids after
their divergence from chimpanzees [12] and confers resis-
tance to Nef [9-11]. The pandemic major (M) group of
HIV-1 managed to switch from Nef to Vpu to counteract
the human tetherin orthologue [10]. In contrast, with a
single documented exception [13], the rare HIV-1 group
N, O, and P strains have apparently thus far failed to
evolve effective antagonists during adaptation to humansLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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been a prerequisite for the efficient spread of the AIDS
pandemic [16]. A recent study suggests that the cytoplas-
mic deletion not only rendered human tetherin resistant
to Nef but also enhanced its ability to act as an innate
sensor of HIV-1 assembly that induces NF-κB-dependent
proinflammatory responses [17].
Like other antiviral host restriction factors, such as
TRIM5α (tripartite motif 5-α) proteins that induce
untimely uncoating of the viral capsid and APOBEC3G
(apolipoprotein B mRNA-editing enzyme, catalytic poly-
peptide-like 3G) that causes lethal hypermutation of the
viral genome, bst2 shows evidence of positive selection
[18,19]. It has been reported that polymorphisms in the
human trim5α, APOBEC3G and bst2 genes are associated
with the clinical course of HIV-1 infection supporting a
relevant role of these restriction factors in vivo [20-25].
Previous investigations of the bst2 gene focused on varia-
tions in the promoter or 3’ untranslated region that
may affect the expression levels of this restriction factor
[25]. Here, we characterized seven rare variants of the
human bst2 gene that change the amino acid sequence
of this restriction factor (Y8H, R19H, N49S, D103N,
E117A, D129E and V146L). We demonstrate that one of
these missense variants, R19H, disrupts the signaling
activity of human tetherin without impairing its ability
to restrict HIV-1 release.
Results
Non-synonymous polymorphisms in the human bst2 gene
A database search of the Exome Variant Server (http://evs.
gs.washington.edu/EVS/), containing data on the exonic
genetic variability of human genes as identified by exome
sequencing of a several thousand individuals of European
and African American descent, was performed in April
2012 to identify potential missense variants of tetherin. As
expected from previous studies [18,19], we did not find
any common non-synonymous polymorphisms in human
bst2 with a minor allele frequency (MAF) > 1%. However,
the initial analysis allowed to identify eight very rare
missense variants (MAF < 0.05%) in different humanTable 1 Non-synonymous polymorphisms in the tetherin ope
Allele c
Amino acid change rsID European American African Am
Y8H rs141648094 G = 4/A = 8596 G = 0/A =
R19H - T = 2/C = 8598 T = 0/C =
N49S rs144978205 C = 6/T = 8594 C = 0/T =
D103N - T = 1/C = 8599 T = 0/C =
E117A - G = 0/T = 8600 G = 1/T =
D129E - C = 0/G = 8600 C = 2/G =
V146L - A = 3/C = 8597 A = 1/C =populations, although one of them (H68Y) was omitted
from the database in subsequent releases and therefore
probably was a false positive finding. Of the remaining
seven missense variants, four (Y8H, R19H, N49S, D103N)
were detected in people of European American descent,
two (E117A, D129E) in African Americans and one
(V146L) in both populations (Table 1). The single nucleo-
tide polymorphisms (SNPs) are distributed throughout the
bst2 gene (Figure 1A). Two of the predicted amino acid
changes (Y8H, R19H) are located in the cytoplasmic N-
terminal region, one (N49S) adjacent to the transmem-
brane domain, and four (D103N, E117A, D129E and
V146L) in the extracellular coiled-coil region (Figure 1B).
Most of these alterations do not affect previously defined
functional domains or structural motifs (Figure 1A), such
as the GPI attachment signal, the two N-linked glycosy-
lation sites or the three cysteine residues that are critical
for homodimerization [6,26]. The exception is Y8H that
affects a non-canonical YxY motif (Figure 1A). It has been
reported that this motif is involved in the endocytic
recycling of tetherin and that its ability to interact with
adaptor protein complexes promotes virion uptake and
subsequent degradation in lysosomes [27].
Missense variants of human tetherin do not impair its
ability to restrict virion release
To examine whether these seven variants may affect the
cell surface expression levels of tetherin, we transfected
293T cells with vectors expressing wild-type and mutant
forms of tetherin and analyzed them by flow cytometry
two days post transfection. Notably, we used two different
antibodies for detection because the E117A substitution
disrupted the previously described epitope (L116-L127) of
the anti-BST-2 antibody from Chugai Pharmaceuticals
[28] (Figure 2A) and the D129E substitution abrogated the
interaction with the eBioscience antibody (Figure 2B). Our
analyses showed that most tetherin variants were expres-
sed as efficiently as wild-type tetherin on the cell surface
(Figure 2B). Only the N49S substitution which is located
just outside of the transmembrane domain (Figure 1B)
significantly reduced the cell surface expression levels ofn reading frame
ount
erican All Conservation (phastCons) Clinical link
4406 G = 4/A = 13002 0.0 Not known
4406 T = 2/C = 13004 0.0 Not known
4406 C = 6/T = 13000 0.591 Not known
4406 T = 1/C = 13005 0.0010 Not known
4405 G = 1/T = 13005 0.135 Not known
4404 C = 2/G = 13004 0.0 Not known
4405 A = 4/C = 13002 0.0 Not known
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Figure 1 Localization of missense variants in human tetherin.
(A) Codons containing non-synonymous variants in the tetherin
gene are boxed in red. Non-synonymous exchanges are indicated
above the nucleotide sequence and the predicted amino acid
changes are shown below the protein frame. The Kozak sequence of
the tetherin gene is highlighted in grey and both alternative start
codons are indicated by arrows. Cysteine residues involved in
dimerization and the two N-linked glycosylation sites are indicated
in yellow and green respectively. ω marks the omega site of GPI
anchor addition. (B) Schematic presentation of the position of the
variants in regard to the structural elements of tetherin. Tetherin is
depicted as a dimer and the two glycosylation sites are indicated.
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N49S variant significantly reduced the total levels of
tetherin expression (Additional file 1: Figure S1). As
expected, the D129E mutation disrupted the epitope of the
eBioscience antibody and the E117A mutation prevented
detection by the Chugai antibody. Although it has been
reported that certain mutations in the cytoplasmic tail may
affect the glycosylation pattern and maturation of tetherin
[17] this was obviously not the case for these naturally oc-
curring polymorphisms (Additional file 1: Figure S1A, B).
Since Y8H alters a previously described non-canonical
YxY endocytosis signal [27], we also analyzed whetherthis mutation may affect the internalization rate of
tetherin. We found that the Y8H variant showed a mark-
edly reduced internalization rate compared to the major
form of human tetherin (Figure 2C). However, the dis-
ruptive effect of the Y8H change alone was less severe
than the combined mutation of both tyrosine residues
(Y6A, Y8A).
To test whether the amino acid variations affect the
anti-retroviral activity of tetherin, we measured infectious
virus yields from 293T cells following cotransfection of a
vpu-deleted HIV-1 proviral construct [29] with various
quantities of tetherin expression plasmid. We found that
all tetherin variants potently inhibited infectious virus re-
lease in a dose-dependent manner and that even the N49S
variant that showed modestly reduced levels of cell surface
expression inhibited virion release as efficiently as wild-
type tetherin (Figure 3). Thus, the seven rare missense
variants analyzed had no significant effect on the ability of
tetherin to restrict HIV-1 release.
Missense variants do not confer resistance to HIV-1 M Vpu
or SIVtan Env
Next, we examined the susceptibility of the tetherin
variants to antagonism by Vpu by cotransfecting 293T
cells with an HIV-1 proviral construct containing an
intact vpu gene and constructs expressing the various
tetherin proteins. As expected from previous studies
[10], the release of wild-type HIV-1 was substantially less
inhibited by tetherin than the vpu-defective derivative
(Figure 4, upper panel). The seven tetherin variants were
all as active against vpu-expressing HIV-1 as wild-type
tetherin (Figure 4). This result implies that these mis-
sense variants do not affect the susceptibility of tetherin
to counteraction by Vpu. Some primate lentiviruses use
their Envelope (Env) proteins instead of Vpu to counter-
act tetherin by targeting the extracellular domain of
tetherin [30,31]. Since most of the tetherin polymor-
phisms are located in the extracellular part we wondered
whether they may confer resistance to Env. To test this,
we analyzed the Envelope protein of SIVtan, infecting
Tantalus monkeys, which has been shown to efficiently
counteract human tetherin [30]. Experiments in transi-
ently transfected 293T cells demonstrated that the
SIVtan Env reduced the surface expression of all tetherin
variants by about 40% (Figure 5A, B) and generally
enhanced infectious virus release (Figure 5C). Thus,
none of the polymorphisms affected the sensitivity of
tetherin to SIVtan Env.
The R19H variant disrupts the signaling activity of human
tetherin
In the following experiments we analyzed the impact of
the seven naturally occurring variants on the signaling
activity of human tetherin [17,32,33]. To examine this,
AB
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Figure 2 Effect of variants on cell surface expression and internalization of tetherin. (A) FACS analysis of 293T cells transfected with
vectors expressing the indicated tetherin variants. Shown are results obtained with the antibody from Chugai Pharmaceuticals (B) Cell surface
expression levels of all tetherin variants. Shown are average values ± SD (n = 2) of the mean fluorescence intensities (MFIs) measured for the
indicated tetherin variants relative to those obtained for the wild-type tetherin protein (100%). (C) Internalization rate of surface tetherin in 293T
cells transfected with the indicated tetherin variants. Shown are average values ± SEM (n = 2).
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plasmids, NF-κB dependent or independent firefly luci-
ferase constructs and a reporter plasmid expressing
gaussia luciferase under the control of a minimal pro-
moter. Dual luciferase assays were performed and the
firefly luciferase signals were normalized to the corre-
sponding gaussia luciferase signals to compensate for
differences in transfection efficiencies. In agreement with
published data [17,33], wild-type tetherin strongly in-
duced NF-κB activation and substitution of the N-
terminal Y residues (Y6A, Y8A) disrupted this effect
(Figure 6A). In contrast, alterations in the extracellular
coiled-coil region of tetherin (D103N, E117A, D129E
and V146L) did not significantly affect the ability of
tetherin to promote NF-κB-dependent gene expression.
Notably, the Y8H polymorphism did not reduce the sig-
naling activity of tetherin either (Figure 6A) indicating
that one N-terminal tyrosine-residue is sufficient for this
function. In agreement with the modest reduction of its
expression at the cell surface (Figure 2), the N49S tetherin
variant showed a weakly but significantly reduced activity
in NF-κB activation (Figure 6A). Most notably however,the R19H substitution significantly reduced the signaling
activity of tetherin (Figure 6A). Thus, this positively
charged arginine residue is critical for the ability of human
tetherin to efficiently induce NF-κB-dependent gene ex-
pression but is dispensable for the restriction of HIV-1
virion release. We confirmed these findings using a
reporter vector that contains six instead of three NF-κB
binding sites and by using 293 instead of 293T cells
(Additional file 2: Figure S2). To exclude artifacts due
to high expression levels of tetherin, we titrated the
tetherin expression vectors over two orders of magnitude.
Activation of NF-κB by the R19H and Y6A, Y8A mutants
was generally reduced (Additional file 2: Figure S2).
To determine tetherin-dependent NF-κB activation in
case of heterozygosity we cotransfected expression vec-
tors for wild-type and R19H tetherin in equal amounts.
Activation of NF-κB was significantly higher in mixed
wt/R19H samples compared to R19H tetherin alone
and comparable to wild-type tetherin (Figure 6B). Thus,
wild-type tetherin is acting in a dominant fashion

































































Figure 3 Effect of variants on the ability of tetherin to restrict virion release. Virus release from 293T cells following transfection with a
vpu-deficient proviral HIV-1 NL4-3 construct and varying amounts of plasmids expressing the indicated tetherin variants. Infectious virus yield was
determined by infection of TZM-bl indicator cells and is shown as a percentage of that detected in the absence of tetherin (100%). Shown are
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Figure 4 Effect of variants on the susceptibility of tetherin to antagonism by Vpu. Virus release from 293T cells following transfection with
the wild-type proviral HIV-1 NL4-3 construct and varying amounts of tetherin expression plasmids. Results obtained with the vpu-deficient proviral
construct are shown in the upper panel for comparison. Infectious virus release was determined as described in the legend of Figure 3. Shown
are average values ± SD derived from two independent experiments, each performed in triplicate.



















































































HIV-1 Env SIVtan Env
Figure 5 Effect of variants on the susceptibility of tetherin to antagonism by SIVtan Env. (A) FACS analysis of 293T cells transfected with
vectors expressing the indicated tetherin variants and SIVtan or HIV-1 M NL4-3 Env. Shown are results obtained with the antibody from
eBioscience. (B) Cell surface expression levels of all tetherin variants. Shown are average values ± SD (n = 3) of the mean fluorescence intensities
(MFIs) measured in the presence of SIVtan Env relative to those obtained in the presence of HIV-1 M NL4-3 Env which served as negative control
(100%). (C) Virus release from 293T cells following transfection with the vpu-deficient proviral HIV-1 NL4-3 construct, an expression vector for
HIV-1 M or SIVtan Env and varying amounts of tetherin expression plasmids. Infectious virus release was determined as described in the legend of
Figure 3. Shown are average values ± SD derived from one experiment, performed in triplicate.
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Figure 6 Impact of variants on the ability of tetherin to activate NF-κB. (A) Activation of NF-κB-dependent firefly luciferase reporter gene
expression in 293T cells transiently cotransfected with tetherin, NF-κB-dependent (three NF-κB binding sites) or -independent firefly luciferase
constructs and a reporter plasmid expressing gaussia luciferase under the control of a minimal promoter. The results show mean values ± SD of
three independent transfections. (B) Equal amounts of vectors expressing wild-type and R19H tetherin were transfected to mimic heterozygosity.
Mean values ± SD of four independent experiments in triplicates are shown.
Sauter et al. Retrovirology 2013, 10:85 Page 6 of 10
http://www.retrovirology.com/content/10/1/85
Sauter et al. Retrovirology 2013, 10:85 Page 7 of 10
http://www.retrovirology.com/content/10/1/85Discussion
In this study, we functionally characterized seven very
rare sequence variants of human tetherin. Our results
show that none of them significantly reduces the ability
of tetherin to restrict HIV release or its sensitivity to
antagonism by HIV-1 Vpu or SIVtan Env. However,
although these variants are very rare and do most likely
not directly affect the control of HIV-1 replication or
transmission, they led to two interesting observations.
First, mutation of Y8H that affected a previously des-
cribed YxY motif in the cytoplasmic tail of tetherin [27]
did not impair its antiviral or signaling activity. Second,
we found that substitution of R19H disrupts the signaling
activity of human tetherin without reducing its capability
to inhibit virus release. Thus, these two key functions of
human tetherin are genetically separable.
Our finding that the Y8H substitution that shows a
minor allele frequency of about 0.05% in Caucasians and
seems to be absent in African Americans (Table 1) did
not significantly affect the antiviral activity of human
tetherin is in agreement with previous findings, showing
that the presence of one of these two tyrosine residues
and not the conservation of an YxY-based motif is criti-
cal for endocytosis of tetherin and its signaling activity
[17,27,33]. Interestingly, however, the Y8H substitution
reduced the internalization rate of tetherin albeit not as
drastically as the double Y6A/Y8A mutation. Thus, our
data confirm, that efficient endocytosis of tetherin is not
required for the activation of NF-κB [17]. Notably, how-
ever, the relevance of the two N-terminal tyrosine residues
for the steady state surface levels and endocytosis of
human tetherin is somewhat controversial. Rollason and
coworkers reported that tetherin was efficiently interna-
lized if Y6 or Y8 were mutated individually, whereas the
double mutant Y6A/Y8A was not endocytosed [34]. In
our experiments, however, the Y8H change clearly re-
duced the internalization rate of tetherin (Figure 2C).
Notably, Rollason et al. mutated the tyrosine residues to
alanine and the introduction of the aromatic histidine
residue may explain the discrepancy. Masuyama et al.
performed similar analyses and described a slightly increa-
sed surface expression of the single mutants compared to
wild-type tetherin but did not observe any change of the
internalization rate [27]. A third study reported that
even the double-mutant Y6A/Y8A was robustly endocyto-
sed indicating that the YxY motif is not required for the
constitutive internalization of tetherin [35].
The disruptive effect of the R19H substitution (MAF of
0.015%) on the signaling activity of tetherin came as a
surprise since the Neil group has previously demonstrated
that amino acids 9 to 11 (CRV) are critical for this func-
tion [17]. In the previous study alanine substitutions at
positions 17 to 21 (DKRCK) impaired tetherin-mediated
signaling but also reduced its steady state expression levelsthus precluding meaningful functional analyses [17].
Notably, Galão and coworkers introduced triple alanine
scanning mutations in the cytoplasmic domain of tetherin.
Thus, their data do not contradict our finding that the
arginine at position 19 is critical for the ability of tetherin
to mediate efficient immune signaling but not for its anti-
viral activity or steady-state surface expression levels. It is
tempting to speculate that both, residues 9 to 11 (CRV)
and R19 may be important for the signaling activity of hu-
man tetherin because they are flanking a putative TRAF6
binding motif. The consensus motif (PxExx[Ar/Ac]) is
only present in human tetherin and the CRV9-11 and R19
residues are flanking this site (CRVPMEDGDKR). Struc-
tural analyses have shown that at least eight amino acid
residues (xxPxExx[Ar/(Ac]) are involved in TRAF6 bind-
ing [36], which may explain why mutation of CRV/AAA
disrupted this interaction [17]. Interestingly, this putative
TRAF6 binding motif emerged due to a hominid-specific
deletion of the DDIWK motif in tetherin. This deletion is
generally absent in tetherin orthologues of non-human
primate species which induce little if any NF-κB activation
[17]. Potentially, this may explain why deletion of the
DDIWK motif enhanced NF-κB activation by an ape
tetherin orthologue and vice versa its reintroduction into
human tetherin severely impaired this signaling activity
[17]. In contradiction to an important functional role of
this putative TRAF6 interaction motif it has been reported
that mutations in this region (P12-D17) do not disrupt
tetherin-mediated signaling [17]. Notably, a recent study by
Tokarev and colleagues could not co-immunoprecipitate
tetherin with TRAF6 [37] and we were also unable to detect
an interaction between tetherin and TRAF6 although we
employed a variety of experimental systems including co-
immunoprecipitations, reporter protein complementation
assays and in vitro binding assays using purified proteins
(data not shown). Thus, further studies on the functional
impact of R19H, the humanoid-specific deletion, and the
potential TRAF6 binding site in tetherin seem highly
warranted.
The missense variants examined in the present study
did not significantly affect the susceptibility of tetherin
to antagonism by HIV-1 group M Vpu or SIVtan Env. It
is noteworthy, however, that other viruses have also
evolved antagonists of tetherin targeting the domains
affected by these polymorphisms. For example, human
Kaposi's sarcoma-associated herpesvirus (KSHV) encodes
the RING-CH E3 ubiquitin ligase K5 that targets K18 in
the cytoplasmic tail of tetherin for ubiquitination and sub-
sequent degradation [38]. Similar to SIVtan, HIV-2 also
uses its envelope glycoprotein to counteract tetherin by
targeting the extracellular domain of this restriction factor
[30,31]. Notably, the HIV-2 Env is only active against
endogenous tetherin [30]. Thus, we were unable to deter-
mine whether the polymorphisms affect the susceptibility
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selective pressure some of the positions that are poly-
morphic in humans or adjacent residues show variations
between different primate species. For example, changes
of YxY to CxY or FxY are found in the tetherin ortholgues
of Sykes’ monkeys, talapoins and new world monkeys,
respectively. Furthermore, talapoin tetherin contains the
R19H changes analyzed in the present study and African
green monkeys, Patas monkeys and Francois’ leaf mon-
keys contain a cysteine instead of an arginine residue at
this position [39]. Thus, it will be of interest to further
examine the effect of these variants analyzed on the
susceptibility of tetherin to various viral antagonists.
The N49S substitution that was detected in European
(MAF of 0.05%) but not in African Americans sig-
nificantly reduced the tetherin surface expression and
signaling activity by about 20% to 30% (Figures 2 and 6).
We did not observe a significant effect of N49S on the
anti-HIV-1 activity of human tetherin although the
mutant tended to be slightly less active than the wild-
type form (Figure 4). Recently, it has been reported that
a 19-base-pair insertion polymorphism in the promoter
region of bst2 may be associated with faster disease pro-
gression and reduced expression levels of this restriction
factor [25]. Whether or not the reduced surface expres-
sion of the N49S tetherin variant has an impact on the
clinical outcome of HIV-1 infection remains to be deter-
mined and this will not be an easy task, given the rarity
of this variant.
Conclusions
We show that seven very rare sequence variants (Y8H,
R19H, N49S, D103N, E117A, D129E and V146L) do not
significantly affect the potency of human tetherin in
inhibiting the release of HIV-1 particles or its sensitivity to
antagonism by HIV-1 Vpu or SIVtan Env. The R19H vari-
ant, however, selectively abrogated the ability of tetherin to
induce NF-κB-dependent gene expression. Thus, inhibition
of virus release and immune sensing are separable func-
tions of human tetherin and the arginine residue at amino
acid position 19 plays a critical role in the latter activity.
Methods
Expression vectors
Bst2 was cloned into the CMV promoter-based pCGCG
expression vector coexpressing DsRed2 as previously
described [10]. Single nucleotide polymorphisms were
inserted using splicing by overlap extension PCR. To
ensure expression of both isoforms [33] the genuine
Kozak sequence was used. The pCAGGS vector express-
ing SIVtan Env was kindly provided by Ravindra Gupta
[30]. The NF-κB firefly luciferase reporter plasmids
containing three or six NF-κB binding sites were kindly
provided by Bernd Baumann.A minimal promoter gaussia luciferase construct was
purchased from Clontech (#631909) and used for nor-
malization. It contains the TATA-like promoter (pTAL)
region from the Herpes simplex virus thymidine kinase
(HSV-TK) that is not responsive to NF-κB. The gaussia
luciferase in the pTAL vector was replaced by firefly luci-
ferase using NcoI/XbaI and the resulting construct was
used as a negative control for the NF-κB reporter plasmid.
Proviral constructs
Generation of the HIV-1 NL4-3-based proviral construct
coexpressing eGFP via an IRES and the vpu-deficient
mutant thereof has been described previously [29,40].
Cell culture and transfections
TZM-bl, 293T and 293 cells were grown under standard
conditions in Dulbecco’s Modified Eagle Medium (DMEM)
supplemented with 10% fetal bovine serum, antibiotics and
L-glutamine. 293T and 293 cells were transfected using the
calcium-phosphate precipitation method.
FACS
To determine the cell surface expression levels of
tetherin, 293T cells were transfected with expression
vectors for GFP (1 μg) and tetherin (4 μg). To analyze
the effect on SIVtan Env on tetherin surface expression
levels, 293T cells were cotransfected with expression
vectors for GFP (1 μg), tetherin (1 μg) and SIVtan Env
(4 μg). Two days post transfection cells were analyzed by
flow cytometry essentially as described previously [13].
Briefly, cells were stained with an unconjugated anti-BST-
2 antibody from Chugai Pharmaceuticals or eBioscience
and an APC-conjugated secondary anti-mouse antibody
(Invitrogen). Fluorescence of stained cells was detected by
two-color flow cytometry and tetherin expression was
determined as mean fluorescence intensity of tetherin-
APC in GFP expressing cells. Notably, the previously
described epitope (L116-L127) of the antibody from
Chugai Pharmaceuticals [28] is disrupted by the E117A
substitution and the D129E substitution impaired the
interaction with the eBioscience antibody (Figure 2).
Western blot
To monitor tetherin expression, 293T cells were trans-
fected with expression vectors for tetherin (2.5 μg) and
GFP (2.5 μg). Two days post transfection cells were
harvested, lysed in M-PER buffer (Thermo Scientific)
and cell lysates were separated in 4-12% Bis-Tris gels
(Invitrogen). After gel electrophoresis proteins were
transferred to PVDF membranes and probed with an
anti-BST-2 antibody from Chugai Pharmaceuticals or
eBioscience. For internal controls, blots were incubated
with antibodies specific for GFP (290-50, abcam) and β-
actin (8227-50, abcam). Subsequently, blots were probed
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and proteins detected using a LI-COR Odyssey scanner.Internalization assay
To determine the internalization rate of tetherin, 293T
cells were cotransfected with GFP and tetherin expression
vectors. 40 h post transfection, surface tetherin was
stained as described above and cells were incubated for 0,
5, 10, 20, 30 or 60 min at 37°C to allow internalization of
tetherin. After incubation, surface staining was removed
with an acidic wash (pH 2.0) in one half of the samples.
The other half remained untreated for normalization. The
amount of stained tetherin was quantified by flow cytome-
try. The internalization rate was determined by dividing
the MFI of the internalized tetherin (samples with acidic
wash) by the MFI of the cells without acidic wash.Virus release assay
To determine the ability of tetherin to restrict the release
of infectious virions, 293T cells were seeded in six-well
plates and transfected with 5 μg of HIV-1 NL4-3 IRES
eGFP (wild-type or vpu-deficient) and different dilutions
of tetherin expression vectors (250, 100, 50, 25, 12.5, and
6.25 ng). To determine the ability of SIVtan Env to
antagonize tetherin, 293T cells were cotransfected with
4 μg of vpu-deficient HIV-1 NL4-3 IRES eGFP, 1 μg of
vectors expressing SIVtan or HIV-1 M NL4-3 Env and
varying amounts of tetherin expression vectors. Two days
post transfection supernatants were harvested and the
yield of infectious HIV-1 was determined by a 96-well
infection assay on TZM-bl indicator cells.NF-κB reporter assay
Transfections for luciferase assays were performed in
96-well plates and each transfection was performed in
triplicates. Tetherin expression plasmids (75 ng) were
transfected in 293T cells along with NF-κB-dependent
or -independent firefly luciferase constructs (125 ng)
and a pTAL promoter gaussia luciferase reporter plas-
mid (25 ng). 48 h post transfection, dual luciferase assays
were performed. Firefly luciferase signals were norma-
lized to the corresponding gaussia luciferase signals.Statistical analysis
All statistical calculations were performed with a two-
tailed unpaired Students-t-test using Graph Pad Prism
Version 5.0. P values <0.05 were considered significant.Variant database
Single nucleotide variants were accessed from the Exome
Variant Server, NHLBI GO Exome Sequencing Project
(ESP), Seattle, WA (URL: ) (April 2012).Additional files
Additional file 1: Figure S1. Expression of tetherin variants: 293T cells
were transiently transfected with expression vectors for the indicated
tetherin variants. Cells were lysed two days post transfection and total
tetherin levels were determined by immunoblotting using anti-tetherin
antibodies from (A) Chugai Pharmaceuticals or (B) eBioscience. GFP and
β-actin served as transfection and loading controls, respectively. (C) The
tetherin signal intensities were quantified and normalized to β-actin. The
mean ± SEM of three independent blots incubated with the anti-BST2
antibody from Chugai Pharmaceuticals is shown.
Additional file 2: Figure S2. Impact of variants on the ability of
tetherin to activate NF-κB. (A) Activation of NF-κB-dependent firefly
luciferase reporter gene expression in 293T or 293 cells transiently
cotransfected with tetherin, NF-κB-dependent or -independent firefly
luciferase constructs and a reporter plasmid expressing gaussia luciferase
under the control of a minimal promoter. 3x and 6x NF-κB indicates a
reporter vector with three or six NF-κB binding sites, respectively. Mean
values ± SD of three independent transfections are shown. (B) Titration of
the tetherin expression vectors. 293T cells were cotransfected with
tetherin, NF-κB-dependent (three NF-κB binding sites) or -independent
firefly luciferase constructs and a reporter plasmid expressing gaussia
luciferase under the control of a minimal promoter. The mean of three
independent transfections is shown.
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